Note: This article does not constitute any investment advice or recommendations; please refer to official/company announcements for authoritative information. This article is solely intended for the introduction of healthcare-related pharmaceuticals and does not serve as a recommendation for treatment regimens (if applicable), nor does it represent the stance of the platform.Reproduction of any article requires prior authorization.
Anhui Anke Biotechnology (Group) Co., Ltd. (stock abbreviation: "ANKEBIO", 300009.SZ) stated in its recently released Investor Relations Activity Record that, by continuously enriching its product pipeline and vigorously cultivating second- and third-growth-curve products, it will effectively reduce the company's operational dependence on a single product and enhance its core competitiveness.Currently, the Company has established a dual-platform layout in the field of in vivo CAR-T (in vivo CAR-T), with its development progress ranking at the forefront in China.According to available information, ANKEBIO is one of the earliest enterprises in China engaged in the research and development, production, and sales of genetically engineered drugs. Rooted in the biomedical sector, the company focuses on three core areas: growth and development, antiviral therapy, and tumor treatment, and has established a full industrial chain integrating R&D, production, and sales. In recent years, through equity investments and project collaborations, the company has proactively positioned itself in strategic fields such as cell therapy, oncolytic viruses, mRNA therapeutics, and regulatory T cell (Treg) therapy, building a diversified R&D system where “independent R&D + collaborative R&D + equity investment” advance synergistically.In 2025, the Company achieved operating revenue of RMB 2.647 billion, a year-on-year increase of 4.36%; net profit attributable to shareholders of the listed company was RMB 735 million, a year-on-year increase of 4%.During this investor relations event, ANKEBIO presented an update on the company's R&D progress in the field of in vivo CAR-T.Among them, the core product of the investee company BoShengJi Medicine Science and Technology (Suzhou) Co., Ltd. (hereinafter referred to as "BoShengJi"), LV009 Injection (in vivo CD19 CAR-T), utilizes an innovative in vivo lentiviral transduction technology. It has currently entered the IIT (Investigator-Initiated Trial, i.e., "researcher-initiated clinical trial") clinical stage. Its safety has been effectively validated, while the relevant efficacy profile will await subsequent IIT data. BoShengJi is a national high-tech enterprise primarily focused on the research and development of breakthrough tumor cellular immunotherapy technologies and cell-based therapeutic products. It specializes in developing internationally leading, breakthrough first-in-class and best-in-class CAR-T cell therapies, with indications covering both hematological malignancies and solid tumors.Another platform, Afana (Hefei Afana Anke Biotechnology Co., Ltd.), is also an investee of ANKEBIO. Its in vivo CAR-T therapy, utilizing lipid nanoparticle (LNP) delivery technology, has likewise entered the IIT clinical stage. Primarily targeting autoimmune diseases and graft-versus-host disease (GvHD), current data demonstrate significant efficacy, and its safety has also been validated.In addition to the aforementioned arrangements, the joint venture Hefei Tairuige ANKEBIO Biotechnology Co., Ltd. focuses on "regulatory T cell (Treg) therapy-related products" and is committed to establishing a leading-in-China, independently innovative pilot-scale cell culture technology platform for regulatory T cells. It plans to be the first in China to conduct investigator-initiated clinical trials on the use of regulatory T cells (Tregs) for the prevention of aGVHD and the treatment of autoimmune diseases.In response to investors' inquiries, ANKEBIO stated that the company has successively appointed two core executives: Dou Changlin as Co-CEO and Chief Scientific Officer, and Yuan Chun as Co-CEO and Chief Commercial Officer, establishing a "R&D + Commercialization" dual-core driving strategy. Dou Changlin will focus on cutting-edge technology R&D, pipeline development, and the translation of innovative research outcomes to enhance the company's R&D efficiency and build a technology development platform for innovative drugs. Yuan Chun will oversee market operations and the establishment of a sales and marketing system, driving the introduction and commercial launch of products aligned with the company's strategic planning. The company noted that this initiative aims to foster synergistic advancement between innovative R&D and commercial operations, striving to realize its "Breakthrough Innovation, 10 Billion in a Decade" target at the earliest opportunity.Article Source: Economic Reference Network
Scan QR Code to Join GroupMastery of CAR-T therapy, stem cell therapy, and geneTherapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Drugs
